Almost 100,000 people in the United States have been diagnosed with sickle cell disease (SCD). About one million people worldwide have the disease. Patients are at risk of death in environments with low oxygen. Doctors warn people with (SCD) to avoid elevations of over 10,000 feet.
Yet Jimi Olaghere not only conquered sickle cell disease but he also conquered Mt. Kilimanjaro, the highest single free-standing mountain above sea level in the world. Jimi set a new high-altitude record. He acknowledged that the climb was difficult but was pleased that it showed the power of gene and cell therapies.
Jimi had participated in one of the first CRISPR therapy (Casgevy) trials offered by Vertex Pharmaceuticals and CRISPR Therapeutics. He believes that this will bring hope to the millions in the world suffering from the disease.
CASGEVY is a one-time gene therapy, but a multi-step process developed to help individuals 12 years or older live without being dependent on blood transfusions. The process involves collecting and editing blood stem cells to manufacture the gene therapy and preparing the patient for administration and follow-up monitoring for possible side effects and recovery.
Reaching the Summit
All 20 team members reached the Kilimanjaro summit, the highest peak in Africa. There is no doubt that the team of brave young scientists raised awareness as well as significant funds to support them. Just as valuable are the meaningful friendships forged on the trail. Jimi emphasizes the importance of making gene therapies for SCD universally accessible.